Coherus Oncology (CHRS) Revenue (2013 - 2026)
Coherus Oncology (CHRS) posted Revenue of $12.3 million for Q1 2026, down 3.44% sequentially from $12.7 million in Q4 2025, and up 61.99% YoY from $7.6 million in Q1 2025.
Coherus Oncology (CHRS) Revenue (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Revenue for 13 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Revenue rose 61.99% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.9 million (up 47.99% YoY) and the FY2025 annual result came in at $42.2 million, up 59.81% from the prior year.
- Revenue retreated to $12.3 million in Q1 2026 per CHRS's latest filing, from $12.7 million in the prior quarter.
- Over five years, Revenue peaked at $91.5 million in Q4 2023 and troughed at $2.3 million in Q1 2024.
- A 5-year average of $32.3 million and a median of $12.7 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2025: Revenue tumbled 92.88% in 2024, then surged 229.25% in 2025.
- Over 5 years, Revenue stood at $45.4 million in 2022, then jumped by 101.81% to $91.5 million in 2023, then sank by 91.55% to $7.7 million in 2024, then surged by 64.85% to $12.7 million in 2025, then slipped by 3.44% to $12.3 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $12.3 million, $12.7 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 14.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.31 Mn |
| Mar 31, 2026 | 12.31 Mn |
| Dec 31, 2025 | 12.75 Mn |
| Sep 30, 2025 | 11.57 Mn |
| Jun 30, 2025 | 10.25 Mn |
| Mar 31, 2025 | 7.60 Mn |
| Dec 31, 2024 | 7.73 Mn |
| Sep 30, 2024 | 6.05 Mn |
| Jun 30, 2024 | 10.30 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 91.52 Mn |
| Sep 30, 2023 | 74.57 Mn |
| Jun 30, 2023 | 58.72 Mn |
| Mar 31, 2023 | 32.44 Mn |
| Dec 31, 2022 | 45.35 Mn |
| Sep 30, 2022 | 45.42 Mn |
| Jun 30, 2022 | 60.15 Mn |
| Mar 31, 2022 | 60.12 Mn |
| Dec 31, 2021 | 73.35 Mn |
| Sep 30, 2021 | 82.50 Mn |